Zydus receives FDA’s ODD for Desidustat for the treatment of beta-thalassemia
Orphan drug designation (ODD) by the USFDA for Desidustat, provides eligibility for a potential seven-year marketing exclusivity subject to the USFDA approval
Orphan drug designation (ODD) by the USFDA for Desidustat, provides eligibility for a potential seven-year marketing exclusivity subject to the USFDA approval
Senores Pharmaceuticals (SPI) acquired 51% stake in Zoraya Pharmaceuticals
Collaboration aims to deliver rapid, lab-quality testing to communities worldwide – making precision health more accessible
Cupid has been allocated approximately 23.4 million units of female condoms per year
Exemestane is a key therapeutic used in the treatment of certain types of breast cancer in postmenopausal women
Bayer remains a key partner in Ginkgo Bioworks’ growing agricultural biologicals platform
The expanded approval allows Kerendia to be prescribed to heart failure patients with a LVEF of 40% or more
Budesonide is indicated for mild to moderate active Crohn's disease involving the ileum and/or the ascending colon in adults and children 8 years of age and olde
This integrated center combines development, testing, evaluation, and industry-academia-research collaboration
Subscribe To Our Newsletter & Stay Updated